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Alice D. Maa, Craig M. Kesslerb, Hamid A.B. Al-Mondhiryc, Robert Z. Gutd
and David L. CooperdTheHemostasis and Thrombosis Research Society Registry
was used to monitor the postapproval use and safety of
recombinant activated factor VII (rFVIIa). The objective of
this article is to evaluate the data from the Hemostasis and
Thrombosis Research Society Registry related to rFVIIa-
treated bleeding episodes in patients with acquired
hemophilia. For each rFVIIa-treated bleeding episode, the
initial dose, total dose, average infused dose, number of
doses, and treatment duration were calculated. Efficacy was
assessed on a three-point scale. Out of the 166 registered
patients with acquired hemophilia, 110 patients were
treated for 237 bleeding episodes (139 rFVIIa treated); the
majority (70%) were in patients older than 60 years. The
most frequently reported bleeding locations were
subcutaneous (40%) and mucosal (32%). Subcutaneous
bleeding episodes were more commonly reported in
women (55% vs. 40% men) and white patients (44 vs. 27%
black). Of the 139 rFVIIa-treated bleeding episodes, rFVIIa
was used as first-line treatment in 127 bleeding episodes.
The median initial dose was 90mg/kg; the median total
dose per episode was 333.5mg/kg. Physician-rated efficacy
of rFVIIa for each bleeding episode was reported as
‘bleeding stopped’ in 85% of bleeding episodes, ‘bleeding
slowed’ in 11% of bleeding episodes, ‘no improvement’ in
4% of bleeding episodes, and was not documented in 10957-5235 Copyright  2016 Wolters Kluwer Health, Inc. All rights reserved.
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download and share the work provided it is properly cited. The work cannot be chanbleeding episode. One thromboembolic event was
reported; transient neurologic symptoms were reported in a
31-year-old postpartum patient after 110 doses of rFVIIa.
Adequate hemostasis was provided for most rFVIIa-treated
bleeding episodes at doses largely conforming to the
package insert. No major safety concerns were reported.
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Acquired hemophilia is a rare disorder (estimated inci-
dence of 1.5 per million per year) marked by the devel-
opment of autoantibodies to factor VIII [1]. Patients with
acquired hemophilia have a prolonged activated partial
thromboplastin time (aPTT) that does not correct with
mixing with normal plasma. In addition, patients typi-
cally have no previous family or personal history of
bleeding. Patients generally present with serious life-
threatening hemorrhages (most commonly widespread
subcutaneous bleeding episodes) as well as excessive
bleeding following trauma, surgery, or cerebral hemor-
rhage [1].
Bypassing agents are typically used to treat bleeding
episodes in patients with acquired hemophilia and
high-titer inhibitors [5 Bethesda units (BU)]. Recom-
binant activated factor VII (rFVIIa; NovoSeven, Novo
Nordisk A/S, Bagsvaerd, Denmark) is the only Food andDrug Administration-approved bypassing agent indi-
cated for use in patients with acquired hemophilia in
the United States. The recommended dose and dose
interval is 70 to 90mg/kg every 2 to 3 h until hemostasis
is achieved [2].
Recently, several European databases and registries [e.g.
United Kingdom Haemophilia Centre Doctors’ Organ-
isation (UKHCDO), European Acquired Haemophilia
(EACH2) Registry, Surveillance des Auto antiCorps au
cours de l’Hemophilie Acquise (SACHA)] have focused
on the management of bleeding episodes in patients with
acquired hemophilia [3–5]. However, these databases
and registries are specific to Europe and may not be
representative of clinical practice in the United States.
The Hemostasis and Thrombosis Research Society
(HTRS) Registry was established as an institutional
review board-monitored Web-based platform with
informed consent in 1999 to support the society’sDOI:10.1097/MBC.0000000000000471
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and Drug Administration approval. Acquired hemo-
philia surveillance was initiated in October 2006. The
HTRS Registry is a multicenter, longitudinal US data-
base that was created to study treatment strategies for
patients with bleeding disorders, including acquired
hemophilia. The objective of this analysis was to evalu-
ate the data from the HTRS Registry related to rFVIIa-
treated bleeding episodes in patients with acquired
hemophilia.
Methods
The HTRS Registry is a longitudinal database of bleed-
ing episodes, surgical procedures, and treatments in
patients with bleeding disorders developed in 1999 as
a joint effort of the then Hemophilia Research Society
(HRS) and Novo Nordisk Inc., with the dual purposes of
serving as a platform for society-based research on bleed-
ing disorders and fulfilling the postmarketing surveil-
lance requirements around rFVIIa. In 2004, the HRS
Registry was relaunched as the HTRS Registry and
included a new Web-based database with Internet data
entry. This retrospective review focuses on data collected
on patients with acquired hemophilia with bleeding
episodes reported in the HTRS Registry.
Data collection
Acquired hemophilia surveillance was initiated in Octo-
ber 2006; however, data on bleeding episodes entered
between January 2004 and November 2011 were ana-
lyzed by investigators to identify patients with acquired
hemophilia who experienced acute bleeding episodes.
Data regarding demographic and baseline characteristics,
efficacy, and safety were presented for patients treated
with rFVIIa. Only demographic and baseline character-
istics data were presented for patients who received
hemostatic treatments other than rFVIIa.
An acute bleeding form was requested to be completed
for each individual bleeding episode. Bleeding episodes
were classified by investigators into the following
categories based on bleeding type: spontaneous, trau-
matic injury, surgical (nondental), dental procedures, and
other medical procedures (e.g. venipuncture, diagnostic
procedures, injection). Bleeding episodes were also
classified based on bleeding location: joint, subcutaneous,
muscular, mucosal, and other locations.
Efficacy assessment
Efficacy was recorded for each treatment regimen and
included information regarding the product used, dosing,
frequency of dosing, and the number of infusions. A
dosing regimen was defined as the dose of the drug
administered at a particular frequency for a particular
number of doses. Information on dosage of rFVIIa was
presented as initial dose (the first dose administered for a
particular bleeding episode), total dose (the sum of alldoses administered for a particular bleeding episode,
including the initial dose), mean dose (the total dose
divided by the total number of doses), the total number of
doses, and the number of treatment days. The total
number of treatment days (including rFVIIa and other
hemostatic agents) was also presented.
The HTRS platform did not require a final resolution to
every bleeding episode, and as such, it was not uncom-
mon for the final treatment to be listed as ‘bleeding
slowed’ or ‘no improvement’ despite no further treat-
ments being administered or despite ‘bleeding stopped’
having been reported for days before end of treatment.
Treatment response was classified by investigators into
the following categories, with subclassifications based on
review of all treatment data and outcomes for that epi-
sode: ‘bleeding stopped,’ ‘bleeding slowed, but not
stopped,’ (with additional subclassifications of ‘no
additional medications given after rFVIIa,’ ‘additional
blood products given after rFVIIa, with bleeding
stopped,’ and ‘additional hemostatic agents given, with
bleeding stopped’), ‘no improvement’ (with additional
subclassifications of ‘no additional medication given after
rFVIIa’ and ‘additional hemostatic agents given, with
bleeding stopped’), or ‘inadequate rFVIIa trial’ for epi-
sodes in which the bleeding did not stop and the rFVIIa
dose administered was considered significantly lower
(30mg/kg) than the recommended dose stated in the
package insert.
For bleeding episodes treated with rFVIIa, additional
information, including the initial and subsequent dosing
for each bleeding episode, was extensively queried and
validated, from which the mean dose per infusion and
total rFVIIa dose, number of doses, and treatment
duration were calculated.
Safety assessment
Safety assessments were based on the occurrence of
adverse events, including thromboembolic events and
deaths, which were recorded in adverse event and
mortality forms, respectively. Severity (mild, moderate,
severe, unknown) of the bleeding episode, duration of
treatment, follow-up action, and outcome were reported
for each adverse event.
Validated adverse event data for rFVIIa are maintained
through the postmarketing surveillance activities in the
HTRS Registry. Serious adverse event reports are sub-
mitted to the respective manufacturers by the registry.
Adverse event data were also queried for any events in
patients treated with rFVIIa.
Statistical analysis
Statistical analyses were performed on the SAS data set
by Outcome Sciences (Cambridge, Massachusetts, USA),
the contract research organization that managed the
registry. Each bleeding episode was individually
HTRS: rFVIIa in acquired hemophilia bleeding episodes Ma et al. 755analyzed for initial and subsequent dosing, from which
the mean and total rFVIIa doses, number of doses, and
treatment duration were calculated. Summary statistics
were derived for relevant subgroups. Median values
and ranges are presented, rather than mean values,
because of outlier bleeding episodes and the nonnormal
data distribution.
Results
Demographics
One hundred sixty-six patients with acquired hemophilia
were enrolled in the HTRS Registry; the detailed demo-
graphics of this population are described elsewhere [6].
Overall, 110 patients were treated for 237 bleeding epi-
sodes. Of the 237 bleeding episodes, 139 (58.6%) epi-
sodes in 68 patients were treated with rFVIIa (89
episodes treated with rFVIIa alone and 50 episodes
treated with rFVIIa and other hemostatic agents and/or
blood components). Of the 98 bleeding episodes, treated
without rFVIIa, 75 episodes (43 patients) were treated
with other hemostatic agents or blood components only,
21 episodes (18 patients) were recorded with no treat-
ment for the episode, and 2 episodes (2 patients) had no
treatment data recorded. The median (range) age of all
registered patients was 70.2 (13–93) years; for rFVIIa-
treated patients with bleeding episodes reported, the
median (range) age was 73.7 (18–93) years (Table 1).
Of the 68 patients with bleeding episodes treated with
rFVIIa, 35 were women and 33 men. Overall, 46 (67.6%)
patients were white, non-Hispanic and 15 (22.1%) wereTable 1 Demographics of patients with acquired hemophilia with blee
Registered
acquired
Number of patients 1
Age at registration (years)
Median (range) 70.2 (
Sex, n (%)
Male 73 (
Female 83 (
Missing 10 (
Ethnicity, n (%)
White, non-Hispanic 102 (
White, Hispanic 15 (
Black, non-Hispanic 38 (
Black, Hispanic 2 (
Other 4 (
Unknown 5 (
Functional status at registration, n (%)
Unrestricted 51 (
Full school/work, limited recreation 11 (
Limited school/work/activities 59 (
Requires assistance, no recreation 27 (
Unknown 18 (
Inhibitor titers, BU
Highest human, anti-VIII, n 1
Median (range) 50 (
Lowest human, anti-VIII, n
Median (range) 1 (
Current human, at the time of the bleed, anti-VIII, n
Median (range) 2.5 (
BU, Bethesda units; rFVIIa, recombinant activated factor VII.black, non-Hispanic. Median age at the time of the
bleeding episode was 68.8 years.
Bleeding episodes
The types of bleeding episodes reported by all patients
and those treated with rFVIIa are presented in Fig. 1a.
The most frequently reported bleeding type was spon-
taneous bleeding (69.6%, 165 episodes), followed by
traumatic bleeds (17.7%, 42 episodes). The most fre-
quently reported bleeding type for rFVIIa-treated bleed-
ing episodes was spontaneous bleeding (68.4%, 95
episodes). Other bleeding types treated with rFVIIa
included traumatic (21.6%), surgical/procedure-related
(5.1%), dental (1.4%), and other (2.9%).
The location of bleeding episodes reported by patients
with acquired hemophilia for all bleeding episodes and
bleeding episodes treated with rFVIIa is presented in
Fig. 1b. A single bleeding episode may have more than
one bleeding location. Subcutaneous bleeding was most
common, occurring in 94 (39.7%) bleeding episodes [53
(38.1%) of rFVIIa-treated episodes]. Other locations for
rFVIIa-treated bleeding episodes included the mucosa
(32.4%), muscle (20.9%), and joint (15.1%).
Of the 237 bleeding episodes with treatment information,
110 occurred in male patients and 127 in female patients.
Overall, the majority of bleeding episodes (n¼ 158, 67%)
occurred in patients who were white and in patients older
than 60 years (n¼ 166, 70%). Subcutaneous bleeding
episodes were more commonly reported in men (45 vs.d episodes treated with rFVIIa
patients with
hemophilia
Registered patients with acquired hemophilia
with bleeding episodes treated with rFVIIa
66 68
13–93) 73.7 (18–93)
44.0) 33 (48.5)
50.0) 35 (48.92)
6.0) 0 (0.0)
61.4) 46 (67.6)
9.0) 4 (5.9)
22.9) 15 (22.1)
1.2) 1 (1.5)
2) 2 (3.0)
3.0) 0 (0.0)
30.7) 16 (23.5)
6.6) 3 (4.4)
35.5) 30 (44.1)
16.3) 17 (25.0)
10.8) 2 (2.9)
26 59
1–2969) 56 (3–2969)
97 42
0–878) 3.3 (0–878)
60 30
0–878) 2.3 (0–878)
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Type and location of rFVIIa-treated bleeding episodes: (a) Type of bleeding episode and bleeding episodes treated with rFVIIa. (b) Location for all
bleeding episodes and bleeding episodes treated with rFVIIa. rFVIIa, recombinant activated factor VII.35% women) and white patients (44 vs. 27% black); there
was no difference based on age. Mucosal bleeding epi-
sodes were more common in black patients (49 vs. 25%
white), and muscle bleeding episodes more common in
white patients (23 vs. 14% black).Recombinant activated factor VII exposure
The median [interquartile range (IQR)] data for rFVIIa
dosing are described in Table 2. The data are not
normally distributed because of a few outlier bleeding
episodes that used much higher doses of rFVIIa
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Table 2 Median (interquartile range) values for rFVIIa dosing and exposure in treatment of bleeding episodes
Total First-line rFVIIa Second-line rFVIIa
Number of episodes 139 127 12
Initial dose (mg/kg) 90 (87.6–100.0) 90 (87.1–100.0) 90 (90.0–97.0)
Dose per infusion (mg/kg) 90 (87.8–98.7) 90 (87.6–98.7) 90 (90.0–97.0)
Total dose per episode (mg/kg) 333.5 (165.8–1382.9) 300 (118.7–1345.3) 576.9 (275.3–3430.0)
Number of injections (doses) 3 (2.0–14.0) 3 (1.0–13.5) 7 (3.5–25.0)
rFVIIa treatment duration (days) 1 (0–2.8) 1 (0–2.5) 1.5 (0.8–4.1)
Total treatment duration (days) 1 (0–4.42) 1 (0–4.0) 7.5 (0.8–13.5)
rFVIIa, recombinant activated factor VII.(180–270mg/kg) or received more doses than other
bleeding episodes, as is evident from the range (1–240
doses) provided. For this reason, the median values are
more appropriate and a descriptive measure of the central
tendency of the data.
Of the 139 rFVIIa-treated bleeding episodes, rFVIIa was
used as first-line treatment in 127 bleeding episodes;
rFVIIa was used as second-line treatment in 12 bleeding
episodes. Overall, the median (IQR) initial rFVIIa dose
was 90 (87.6–100.0) mg/kg, and the mean dose per infu-
sion was 90 (87.8–98.7) mg/kg. The median (IQR) total
dose per episode was 333.5 (165.8–1382.9) mg/kg admin-
istered with a median (IQR) number of 3 (2.0–14.0)
injections over 1 (0–2.8) day. Recombinant FVIIa was
first-line treatment in 51 of 52 (98.1%) subcutaneous
bleeding episodes and 36 of 45 (80.0%) mucosal bleeding
episodes (Table 3). The total dose for mucosal bleeding
episodes (median, 360mg/kg; IQR, 180.0–1350.0) was
lower than that for subcutaneous bleeding episodes
(median, 540mg/kg; IQR, 264.1–1477.3).
Concomitant hemostatic medications or blood products
Concomitant hemostatic medications were administered
in addition to rFVIIa for the treatment of 50 bleeding
episodes (36.0%) (Table 4). The most common concom-
itant medications included packed red blood cells
(pRBCs) (29 episodes, 20.9%) and FEIBA VH (factor
VIII inhibitor bypassing activity, vapor heated; Baxter
Healthcare Corporation, Westlake Village, California,
USA) [activated prothrombin complex concentrate
(aPCC)] (16 episodes, 11.5%). Although pRBCs are a
blood product and not considered to be a hemostatic
agent, the use of pRBCs may be indicative of the severity
of the bleeding episode, and pRBCs were captured in the
HTRS Registry as a concomitant blood product.Table 3 Median (interquartile range) values for rFVIIa dosing and expo
Total
Number of episodes 139
Treatment sequence, n (%)
First line 127 (91.4)
Total dose per episode (mg/kg) 333.5 (165.8–1382.9)
Number of injections (doses) 3 (2.0–14.0)
rFVIIa treatment duration (days) 1 (0–2.75)
rFVIIa, recombinant activated factor VII.Efficacy and safety
Hemostatic response of bleeding episodes to rFVIIa
treatment is presented in Fig. 2. Physician-rated efficacy
of rFVIIa for each bleeding episode was reported as
‘bleeding stopped’ in 118 (85%) episodes, ‘bleeding
slowed’ in 15 (11%) episodes, and ‘no improvement’ in
five (4%) episodes, and was not documented in one
episode. Considering that only four of 139 rFVIIa-treated
episodes (3%) reported treatment failure and that bleed-
ing was stopped after switching to another agent, overall
rFVIIa efficacy was 97%. Bleeding stopped in 87% of
bleeding episodes when rFVIIa was the first line of
treatment compared with 67% when rFVIIa was the
second line of treatment.
Five treatment-emergent adverse events were reported
for three patients in the HTRS Registry from January
2004 to November 2011. One patient reported extension
of a thigh hematoma. One serious adverse event was
reported in a 77-year-old man treated with rFVIIa for
traumatic subcutaneous bleeding. During treatment, the
patient reported moderate anemia, and a red blood cell
transfusion was performed. Mild cough and headache
were also reported during the bleeding episode. None of
the reported treatment-emergent adverse events are con-
sidered to be related to rFVIIa treatment based on
investigator assessment. No other events have been
reported via HTRS after 2008 for patients with acquired
hemophilia treated with rFVIIa.
The only thromboembolic event was transient neurologic
symptoms (transient ischemic attack) in a 31-year-old post-
partum patient after 110 doses of rFVIIa. The woman
developed a muscular hemorrhage during a caesarean sec-
tion and was treated with fresh frozen plasma (1 ml/kg as
needed, to a total of six doses) over a 3-day period, 24 units
of pRBCs over an unknown period, and platelets (dosingsure in treatment of mucosal and subcutaneous bleeding episodes
Mucosal Subcutaneous
45 52
36 (80.0) 51 (98.1)
360 (180.0–1350.0) 540 (264.1–1477.3)
3 (2.0–12.0) 4 (3.0–14.0)
1 (0–2.0) 1 (0–2.6)
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Table 4 Concomitant hemostatic medications or blood products
Hemostatic agent Total
Number of episodes 139
Concomitant hemostatic medications, n (%) 50 (36.0)
Any concomitant medication except blood products 18 (13.0)
Only blood products 20 (14.4)
Blood products, n (%) 32 (23.0)
FFP 7 (5.0)
pRBCs 29 (20.9)
Other blood bank products 3 (2.2)
PCC/aPCC, n (%) 17 (12.2)
FEIBA VH (aPCC) 16 (11.5)
Autoplex T (aPCC) 1 (0.7)
Plasma-derived clotting factor, n (%) 1 (0.7)
Recombinant clotting factor, n (%) 2 (1.4)
Nonplasma product, n (%) 11 (7.9)
Amicar (aminocaproic acid) 5 (3.6)
DDAVP (desmopressin acetate) 3 (2.2)
Other nonplasma products 4 (2.9)
aPCC, activated prothrombin complex concentrate; FEIBA VH, factor VIII inhibitor
bypassing activity, vapor heated; FFP, fresh frozen plasma; pRBCs, packed red
blood cells.information unknown), without improvement. Sub-
sequently, the patient began treatment with rFVIIa
(90mg/kg every 2 h), and the bleeding episode was resolvedFig. 2
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Total (n = 139) First-line rFVII
Treatment efficacy of rFVIIa. Efficacy for all bleeding episodes treated with r
therapy (n¼127), and bleeding episodes in which rFVIIa was used as secafter 72 h. Despite resolution of the bleeding episode,
rFVIIa treatment regimen was continued for an additional
7 days. The patient developed an acute cerebrovascular
accident with weakness in the right leg and upper Babinski
reflex. Magnetic resonance imaging revealed multiple
small infarcts bilaterally in the frontal lobes. The neurol-
ogist reported that it was most likely related to eclampsia
and vasculitis given the patient’s medical history.
Discussion
The final analysis of the HTRS Registry represents the
second largest data set in acquired hemophilia (the lar-
gest in North America) and was the first to examine
symptoms by race and ethnicity [6]. Although sub-
cutaneous bleeding as a first location for a bleeding
episode was uncommon outside of whites, it represents
the most common location of recorded bleeding episodes
in all race/ethnicity groups. In a recent publication
regarding the demographics and management of bleed-
ing in patients with acquired hemophilia in Europe
(EACH2 Registry), a total of 482 patients experienced
at least one bleeding episode [3,7]. Similar to the HTRS3.6 
0.72 
2.4 
0.79 
16.7 
0 
No improvement No outcome reported 
a (n = 127) Second-line rFVIIa (n = 12) 
FVIIa (n¼139), bleeding episodes in which rFVIIa was used as first-line
ond-line therapy (n¼12). rFVIIa, recombinant activated factor VII.
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episode in the EACH2 Registry was spontaneous
(77.4%), and the most common location was sub-
cutaneous (53.2%) [7]. The UKHCDO study also showed
that of 149 patients identified in the United Kingdom,
the most common bleeding site was subcutaneous
(80%) [5].
Of the 237 bleeding episodes reported in the HTRS
Registry, 139 (59%) were treated with rFVIIa (127 first
line), with only 16 episodes (11.5%) treated with aPCC.
This is similar to the treatment pattern reported in the
EACH2 Registry, in which 56.7% of bleeding episodes
were treated with rFVIIa and 20.5% with aPCC as first-
line therapy [3]. In the EACH2 Registry, 69 patients
needed second-line treatment, most commonly due to
lack of efficacy of first-line treatment (50 patients) [3].
Second-line therapy included rFVIIa (36.9%), aPCC
(23.1%), and FVIII (35.4%) [3]. In the UKHCDO study,
32.9% of patients were treated with aPCC and 31.5%
were treated with rFVIIa; however, hemostatic response
was not reported [5].
In the HTRS Registry, efficacy was higher when rFVIIa
was used as first-line therapy (86.6%) than second-line
therapy (66.7%). This is similar to the observed efficacy
of rFVIIa in EACH2, in which 91.2% of bleeding
episodes responded to first-line treatment with rFVIIa,
with fewer bleeding episodes (79.4%) resolving in
response to second-line therapy (efficacy by therapy
was not provided) [3]. This lower efficacy in second-line
treatment may indicate more serious and difficult to
treat bleeding episodes. It was also noted in EACH2
that the efficacy of bypassing agents as first-line therapy
was higher than that of replacement therapy (91.8% vs.
69.6%, P< 0.003) [3].
Dosing of rFVIIa
The current recommended dosing of rFVIIa for
the treatment of bleeding episodes in patients with
acquired hemophilia is 70 to 90mg/kg every 2 to 3 h
until hemostasis is achieved [2]. The median initial
dose and mean dose per infusion (90 and 90mg/kg,
respectively) with a narrow IQR (87.6–100.0 and
87.8–98.7mg/kg, respectively) indicate that treatment
is generally in line with the rFVIIa package insert. This is
also in line with the use of rFVIIa in the EACH2
Registry, in which the median (IQR) dose of rFVIIa
was 90mg/kg (84.71–102.86mg/kg) [3]. However, the
number of doses per bleeding episode was higher in
the EACH2 Registry than the HTRS Registry (median
12 vs. 3) [3]. Covariates that might account for differ-
ences were not uniformly captured across these two
registries, and standardized scales of bleeding episode
severity are not available.
The median number of injections of rFVIIa and total
dose per episode were higher when rFVIIa was used assecond-line treatment compared with first-line treat-
ment, indicating that these bleeding episodes were more
difficult to treat. However, rFVIIa may have been used
as salvage therapy after blood products, aPCC, and/or
antifibrinolytics failed to stop the bleeding, and could
also indicate that these bleeding episodes were more
serious and therefore required additional doses of
rFVIIa to control bleeding. It is also of note that sub-
cutaneous bleeding episodes required a higher number
of injections of rFVIIa and total dose of rFVIIa, com-
pared with mucosal bleeding episodes, indicating that
subcutaneous bleeding episodes may be more difficult
to treat.
Limitations
As this registry was originally intended in part to track the
safety of rFVIIa, the proportion of bleeding episodes
treated with rFVIIa (59%) and associated data derived
from those bleeding episodes may be somewhat biased
and selective. Nevertheless, they certainly indicate that
rapid and safe hemostasis can be achieved with rFVIIa in
an aging population with acquired hemophilia in whom
thrombogenicity is of concern. In addition, as reported
previously, only a limited number of sites contributed to
the HTRS Registry, and therefore, the data set may be
biased toward patients in those regions [6].
Conclusions
The HTRS Registry represents the largest data set in
North America that has reported on demographics and
bleeding episodes in patients with acquired hemophilia.
This analysis of bleeding episodes shows that rFVIIa is an
effective treatment option for patients with acquired
hemophilia. The lower efficacy and increased number
of doses of rFVIIa used in second-line treatment of
bleeding episodes is most likely because the bleeding
episodes were more severe and difficult to treat. Recom-
binant FVIIa is an important treatment option as first-line
therapy in patients with acquired hemophilia. There
were no new safety issues identified, with one throm-
boembolic event (transient neurologic symptoms) occur-
ring in a 31-year-old postpartum patient after 110 doses
of rFVIIa.
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